Cutler Investment Counsel LLC Has $7.55 Million Stock Holdings in Becton, Dickinson and Company $BDX

Cutler Investment Counsel LLC cut its position in Becton, Dickinson and Company (NYSE:BDX) by 0.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 43,826 shares of the medical instruments supplier’s stock after selling 225 shares during the period. Cutler Investment Counsel LLC’s holdings in Becton, Dickinson and Company were worth $7,549,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company in the first quarter worth $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company in the first quarter worth $27,000. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company in the first quarter worth $29,000. Cornerstone Planning Group LLC raised its holdings in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company in the first quarter worth $31,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 over the last quarter. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of a number of research analyst reports. Wells Fargo & Company raised their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price objective on the stock. Piper Sandler restated a “neutral” rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Argus raised their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Stock Up 0.1%

Shares of BDX stock opened at $186.76 on Tuesday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm’s fifty day moving average price is $190.23 and its two-hundred day moving average price is $185.45. The firm has a market capitalization of $53.53 billion, a P/E ratio of 33.59, a PEG ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.